205 related articles for article (PubMed ID: 28581397)
1. Thyroid V40 Predicts Primary Hypothyroidism After Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma.
Sommat K; Ong WS; Hussain A; Soong YL; Tan T; Wee J; Fong KW
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):574-580. PubMed ID: 28581397
[TBL] [Abstract][Full Text] [Related]
2. Thyroid V40 is a good predictor for subclinical hypothyroidism in patients with nasopharyngeal carcinoma after intensity modulated radiation therapy: a randomized clinical trial.
Xu Y; Peng H; Su G; Cheng Y; Guo Q; Guo L; Peng XE; Ke J
Radiat Oncol; 2023 Aug; 18(1):141. PubMed ID: 37626342
[TBL] [Abstract][Full Text] [Related]
3. Thyroid V
Zhou L; Chen J; Shen W; Chen ZL; Huang S; Tao CJ; Chen M; Yu ZH; Chen YY
Radiat Oncol; 2020 Mar; 15(1):68. PubMed ID: 32293496
[TBL] [Abstract][Full Text] [Related]
4. Thyroid dose-volume thresholds for the risk of radiation-related hypothyroidism in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy-A single-institution study.
Huang CL; Tan HW; Guo R; Zhang Y; Peng H; Peng L; Lin AH; Mao YP; Sun Y; Ma J; Tang LL
Cancer Med; 2019 Nov; 8(16):6887-6893. PubMed ID: 31560840
[TBL] [Abstract][Full Text] [Related]
5. Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: Clinical and dosimetric predictors in a prospective cohort study.
Zhai RP; Kong FF; Du CR; Hu CS; Ying HM
Oral Oncol; 2017 May; 68():44-49. PubMed ID: 28438291
[TBL] [Abstract][Full Text] [Related]
6. Hypothalamic-pituitary-thyroid dysfunction induced by intensity-modulated radiotherapy (IMRT) for adult patients with nasopharyngeal carcinoma.
Huang S; Wang X; Hu C; Ying H
Med Oncol; 2013 Dec; 30(4):710. PubMed ID: 23999842
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic Nasopharyngeal Carcinoma.
Lee V; Chan SY; Choi CW; Kwong D; Lam KO; Tong CC; Sze CK; Ng S; Leung TW; Lee A
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e52-60. PubMed ID: 27235379
[TBL] [Abstract][Full Text] [Related]
8. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer.
Diaz R; Jaboin JJ; Morales-Paliza M; Koehler E; Phillips JG; Stinson S; Gilbert J; Chung CH; Murphy BA; Yarbrough WG; Murphy PB; Shyr Y; Cmelak AJ
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):468-76. PubMed ID: 19577867
[TBL] [Abstract][Full Text] [Related]
9. Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin's lymphoma.
Cella L; Conson M; Caterino M; De Rosa N; Liuzzi R; Picardi M; Grimaldi F; Solla R; Farella A; Salvatore M; Pacelli R
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1802-8. PubMed ID: 21514076
[TBL] [Abstract][Full Text] [Related]
10. Predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma survivors after intensity-modulated radiotherapy.
Zhai R; Lyu Y; Ni M; Kong F; Du C; Hu C; Ying H
Radiat Oncol; 2022 Mar; 17(1):57. PubMed ID: 35313921
[TBL] [Abstract][Full Text] [Related]
11. Radiation-induced nasopharyngeal ulcers after intensity modulated radiotherapy in primary nasopharyngeal carcinoma patients: A dose-volume-outcome analysis.
Li Y; Xu T; Qian W; Lu X; Hu C
Oral Oncol; 2018 Sep; 84():1-6. PubMed ID: 30115466
[TBL] [Abstract][Full Text] [Related]
12. Validation of previously reported predictors for radiation-induced hypothyroidism in nasopharyngeal cancer patients treated with intensity-modulated radiation therapy, a post hoc analysis from a Phase III randomized trial.
Lertbutsayanukul C; Kitpanit S; Prayongrat A; Kannarunimit D; Netsawang B; Chakkabat C
J Radiat Res; 2018 Jul; 59(4):446-455. PubMed ID: 29750261
[TBL] [Abstract][Full Text] [Related]
13. Pattern of radiation-induced thyroid gland changes in nasopharyngeal carcinoma patients in 48 months after radiotherapy.
Lin Z; Yang Z; He B; Wang D; Gao X; Tam SY; Wu VWC
PLoS One; 2018; 13(7):e0200310. PubMed ID: 29985952
[TBL] [Abstract][Full Text] [Related]
14. Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.
Tan T; Lim WT; Fong KW; Cheah SL; Soong YL; Ang MK; Ng QS; Tan D; Ong WS; Tan SH; Yip C; Quah D; Soo KC; Wee J
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):952-60. PubMed ID: 25832687
[TBL] [Abstract][Full Text] [Related]
15. Radiation-induced hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy with or without chemotherapy: Development of a nomogram based on the equivalent dose.
Zhu MY; Wu HJ; Miao JJ; Di MP; Chen BY; Huang HG; Mai HQ; Wang L; Zhao C
Oral Oncol; 2021 Sep; 120():105378. PubMed ID: 34174518
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of early thyroid dysfunction after definitive radiotherapy in nasopharyngeal carcinoma patients.
Lian CL; Zhuo RG; Zhou R; Yu YF; Zhou P; Lin Q; Wu SG
Head Neck; 2023 Sep; 45(9):2344-2354. PubMed ID: 37415457
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
Wu M; Ou D; He X; Hu C
Oral Oncol; 2017 Oct; 73():118-123. PubMed ID: 28939063
[TBL] [Abstract][Full Text] [Related]
18. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J
JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J
Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073
[TBL] [Abstract][Full Text] [Related]
20. Thyroid V50 Highly Predictive of Hypothyroidism in Head-and-Neck Cancer Patients Treated With Intensity-modulated Radiotherapy (IMRT).
Sachdev S; Refaat T; Bacchus ID; Sathiaseelan V; Mittal BB
Am J Clin Oncol; 2017 Aug; 40(4):413-417. PubMed ID: 25503434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
